A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

NCT02138734 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

369

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-muscle Invasive Bladder Cancer

Interventions

BIOLOGICAL: BCG (50mg/instillation) + N-803 (400 μg/instillation)
BIOLOGICAL: BCG (50mg/instillation)

Sponsor

ImmunityBio, Inc.